Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial-Reference-Cited by-同舟云学术

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

Published:2022-03-02 Issue:2 Volume:52 Page:129-136
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Ruwaard J¹,L’ Ami MJ¹,Kneepkens EL¹,Krieckaert CLM²,Nurmohamed MT¹²^ORCID,Hooijberg F¹,van Kuijk AWR¹,van Denderen JC¹,Burgemeister L¹,Rispens T³^ORCID,Boers M¹²⁴,Wolbink GJ¹³^ORCID

Affiliation:

1. Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands

2. Department of Rheumatology, Amsterdam UMC | Vrije Universiteit, Amsterdam, The Netherlands

3. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, Amsterdam, The Netherlands

4. Department of Epidemiology and Data Science, Amsterdam UMC | Vrije Universiteit, Amsterdam, The Netherlands

Funder

Stichting Achmea Gezondheidszorg with projectnumber: Z593

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2022.2028364

Reference24 articles.

1. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial

2. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

3. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

4. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial(STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)

5. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial;Rheumatology International;2024-07-24

2. Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review;International Immunopharmacology;2024-06

3. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis;Annals of the Rheumatic Diseases;2024-03-19

4. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update;Annals of the Rheumatic Diseases;2024-03-18

5. Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings);Current Rheumatology Reports;2024-02-09